Stock Scorecard



Stock Summary for Aldeyra Therapeutics Inc (ALDX) - $1.78 as of 4/10/2026 8:23:53 PM EST

Total Score

10 out of 30

Safety Score

24 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ALDX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ALDX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ALDX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ALDX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ALDX (24 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ALDX

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky 4/13/2026 7:08:00 PM
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! 4/13/2026 12:08:00 PM
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 4/13/2026 10:08:00 AM
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm 4/12/2026 3:38:00 PM
Rosen Law Firm Encourages Aldeyra Therapeutics Investors to Secure Counsel Before Upcoming Deadline 4/12/2026 8:10:00 AM
Did You Lose Money Investing in Aldeyra Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against ADLX 4/11/2026 10:10:00 AM
ALDX Shareholder Alert: Investors With Losses May Seek to 4/10/2026 10:38:00 PM
ALDX Forecast, Price Target & Analyst Ratings | ALDEYRA THERAPEUTICS INC (NASDAQ:ALDX) 4/10/2026 10:38:00 PM
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors 4/10/2026 10:09:00 PM
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm 4/10/2026 9:01:00 PM

Financial Details for ALDX

Company Overview

Ticker ALDX
Company Name Aldeyra Therapeutics Inc
Country USA
Description Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/13/2026

Stock Price History

Last Day Price 1.78
Price 4 Years Ago 6.96
Last Day Price Updated 4/10/2026 8:23:53 PM EST
Last Day Volume 2,250,359
Average Daily Volume 5,184,915
52-Week High 6.17
52-Week Low 1.07
Last Price to 52 Week Low 66.36%

Valuation Measures

Trailing PE N/A
Industry PE 43.01
Sector PE 38.13
5-Year Average PE -5.29
Free Cash Flow Ratio 1.53
Industry Free Cash Flow Ratio 14.85
Sector Free Cash Flow Ratio 22.07
Current Ratio Most Recent Quarter 2.58
Total Cash Per Share 1.16
Book Value Per Share Most Recent Quarter 0.74
Price to Book Ratio 2.42
Industry Price to Book Ratio 105.79
Sector Price to Book Ratio 23.58
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 16.68
Sector Price to Sales Ratio Twelve Trailing Months 5.73
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 60,183,000
Market Capitalization 107,125,740
Institutional Ownership 65.70%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 39.40%
Reported EPS 12 Trailing Months -0.56
Reported EPS Past Year 0.00
Reported EPS Prior Year -0.57
Net Income Twelve Trailing Months -33,846,661
Net Income Past Year -33,846,661
Net Income Prior Year -55,851,444
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 70,041,254
Total Cash Past Year 70,041,254
Total Cash Prior Year 54,527,092
Net Cash Position Most Recent Quarter 54,942,725
Net Cash Position Past Year 55,041,254
Long Term Debt Past Year 15,000,000
Long Term Debt Prior Year 15,000,000
Total Debt Most Recent Quarter 15,098,529
Equity to Debt Ratio Past Year 0.75
Equity to Debt Ratio Most Recent Quarter 0.75
Total Stockholder Equity Past Year 44,250,390
Total Stockholder Equity Prior Year 71,004,871
Total Stockholder Equity Most Recent Quarter 44,250,390

Free Cash Flow

Free Cash Flow Twelve Trailing Months -33,345,686
Free Cash Flow Per Share Twelve Trailing Months -0.55
Free Cash Flow Past Year -33,345,682,000,000
Free Cash Flow Prior Year -43,208,747

Options

Put/Call Ratio 0.39
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 1.30
20-Day Bollinger Middle Band 4.12
20-Day Bollinger Upper Band 6.95
Beta 1.33
RSI 33.67
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 4/13/2026 4:55:50 PM EST